A study of topiramate pharmacokinetics and tolerability in children with epilepsy

Pediatric Neurology

Volumn 20, Issue 5, 1999, Pages 339-344

  Rosenfeld, William E ^a   Doose, Dennis R ^b   Walker, Sally A ^b   Baldassarre, James S ^b   Reife, Ross A ^b  

^a Compreh Epilepsy Care Ctr C ^*  (United States)

^b Robert Wood Johnson P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; ENZYME INDUCING AGENT; ETHOTOIN; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE;

ADOLESCENT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FEMALE; HUMAN; MALE; NERVOUSNESS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

ADOLESCENT; AGE FACTORS; ANTICONVULSANTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; EPILEPSY; FEMALE; FRUCTOSE; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033008971     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(99)00011-9     Document Type: Article

References (23)

1. Maryanoff B.E., Nortey S.O., Gardocki J.F., Shank R.P., Dodgson S.P. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-bis-O-(1-methylethylidene)-D-fructopyranose sulfamate and related compounds. J Med Chem. 30:1987;880-887.
2. Rogawski M.A., Porter R.J. Antiepileptic drugs Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds . Pharmacol Rev. 42:1990;223-286.
3. Coulter D.A., Sombati S., DeLorenzo R.J. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. [abstract] Epilepsia. 34:(Suppl 2):1993;123.
4. Brown S.D., Wolf H.H., Swinyard E.A., Twyman R.F., White H.S. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. [abstract] Epilepsia. 34:(Suppl 2):1993;122-123.
5. Severt L., Coulter D.A., Sombati S., DeLorenzo R.J. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. [abstract] Epilepsia. 36:(Suppl 4):1995;38.
6. Bialer M. Comparative pharmacokinetics of the newer antiepileptic drugs. Clin Pharmacokinet. 24:1993;441-452.
7. Easterling D.E., Zakszewski T., Moyer M.D., Margul B.L., Marriott T.B., Nayak R.K. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. [abstract] Epilepsia. 29:1988;662.
8. Doose D.R., Scott V.V., Margul B.L., Marriott T.B., Nayak R.K. Multiple-dose pharmacokinetics of topiramate in healthy male subjects. [abstract] Epilepsia. 29:1998;662.
9. Wu W.N., Heebner J.B., Streeter A.J., Moyer M.D., Takacs A.R., Doose D.R., Ferraiolo B.L. Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men. [abstract] Pharm Res. 11:1994;S336.
10. Gisclon L.G., Curtin C.R., Kramer L.D. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin®) and topiramate (Topamax®) in epileptic patients on monotherapy, and during combination therapy. [abstract] Epilepsia. 35:(Suppl 8):1994;54.
11. Sachdeo R.C., Sachdeo S.K., Walker S.A., Kramer L.D., Nayak R.K., Doose D.R. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 37:1996;774-780.
12. Rosenfeld W.E., Liao S., Kramer L.D., et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy on monotherapy and concomitant therapy. Epilepsia. 38:1997;324-333.
13. Sharieff M., Viteri C., Ben-Menachem E., et al. Double-blind, placebo-controlled study of topiramate in patients with refractory epilepsy. Epilepsy Res. 25:1996;217-224.
14. Tassinari C.A., Michelucci R., Chauvel P., et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 37:1996;763-768.
15. Ben-Menachem E., Henriksen O., Dam M., et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 36:1996;539-543.
16. Faught E., Wilder B.J., Ramsay R.E., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400- and 600-mg daily dosages. Neurology. 46:1996;1684-1690.
17. Privitera M., Fincham R., Penry J., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology. 46:1996;1678-1683.
18. Pledger G., Reife R.A., Lim P., Karim R. Overview of topiramate efficacy from adjunctive therapy trials. (abstract) Epilepsia. 36:(Suppl 3):1995;S150.
19. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu S-C, Pledger G, Topiramate YP Study Team. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology, in press.
20. Sachdeo RC, Glauser TA, Ritter FJ, Reife R, Lim P, Pledger G, Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology, in press
21. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology, in press.
22. French J.A., Leppik I. Testing antiepileptic drugs in children. J Child Neurol. 9:(Suppl1):1994;S26-S32.
23. Bourgeois B.F.D. Antiepileptic drugs in pediatric practice. Epilepsia. 36:(Suppl 2):1995;S34-S45.